TRVN - Trevena, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.43
-0.05 (-3.38%)
At close: 4:00PM EDT

1.50 +0.07 (4.90%)
Pre-Market: 8:14AM EDT

Stock chart is not supported by your current browser
Previous Close1.48
Open1.48
Bid1.41 x 2200
Ask1.50 x 800
Day's Range1.39 - 1.49
52 Week Range1.34 - 3.00
Volume1,337,577
Avg. Volume1,056,001
Market Cap103.793M
Beta-0.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE9 days ago

    Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on TRVN sign up now at www.wallstequities.com/registration. On Monday, July 09, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green.

  • GlobeNewswire21 days ago

    Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine

    Trevena, Inc. (TRVN) announced today the successful completion of its first-time-in-human Phase 1 study of TRV250, a biased delta receptor agonist that the Company is developing for the treatment of acute migraine.  Preclinical data suggested that the novel selective signaling mechanism of TRV250 might avoid the seizure liability that has limited development of therapeutics targeting the delta receptor.  Data from this healthy volunteer study showed safety, tolerability, and pharmacokinetics supporting the advancement of TRV250 to Phase 2 proof of concept evaluation in patients.

  • GlobeNewswirelast month

    Trevena Expands Commercial and Medical Affairs Leadership Teams with Key Hires

    The Company has appointed Linda Wase, M.D. as Vice President of Medical Affairs, Michael Catalano as Vice President of Marketing, and Bob Yoder as Vice President of Sales & Commercial Operations. Linda Wase, M.D., has worked with Trevena since 2017, first as a consultant guiding Medical Affairs strategy and, since March 2018, as Vice President of Medical Affairs.

  • ACCESSWIRElast month

    TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space

    LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).

  • GlobeNewswire2 months ago

    Trevena to Present at the Jefferies Global Healthcare Conference

    CHESTERBROOK, Pa., May 30, 2018-- Trevena, Inc. today announced that it will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 6 th, 2018, at 3:30 p.m. EDT in New York, NY.. ...

  • ACCESSWIRE2 months ago

    Blog Exposure - Trevena Showcases Data from ATHENA Phase-3 Study at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Trevena,Inc. (NASDAQ: TRVN), all you need to do is sign up now by clicking thefollowing link www.active-investors.com/registration-sg/?symbol=TRVN as the Company’s latest news hit the wire. OnMay 22, 2018, the Company, which is a biopharmaceutical organization developinginnovative therapies based on breakthrough science to benefit patients and healthcareproviders confronting serious medical conditions, announced that it showcasedtwo presentations at the American Society of Colon and Rectal Surgeons 2018Annual Scientific Meeting. Active-Investors.com is currently working on the researchreport for Albireo Pharma, Inc. (NASDAQ: ALBO), which also belongs to the Healthcaresector as the Company Trevena.

  • GlobeNewswire2 months ago

    Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

    Trevena, Inc. (TRVN) today announced two presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting, held in Nashville, Tennessee, May 19-23. The first poster highlighted efficacy, safety and tolerability data from 115 colorectal patients from the ATHENA Phase 3 multicenter, open label safety study of Trevena's investigational product oliceridine. In the ATHENA study, oliceridine was administered to 768 patients with moderate-to-severe acute pain caused by medical conditions or surgery.

  • GlobeNewswire2 months ago

    Trevena Appoints Mark A. Demitrack, M.D., as Chief Medical Officer

    “Mark is a highly experienced pharmaceutical executive, with comprehensive experience developing therapeutics, shepherding them through the approval process, and leading post approval activities,” said Maxine Gowen, Ph.D., Chief Executive Officer. The Company also announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 21, 2018, the grant of inducement stock options to purchase 200,000 shares of the Company's common stock to Dr. Demitrack.

  • GlobeNewswire2 months ago

    Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Trevena, Inc. (TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 2, 2018, the grant of inducement stock options to purchase 27,000 shares of the Company's common stock to Richard Zimet, a new employee. The stock option has an exercise price per share of $2.07, the closing stock price on May 2, 2018.

  • GlobeNewswire3 months ago

    Trevena Reports First Quarter 2018 Financial Results

    –First license agreements for ex-US development and commercialization of oliceridine add potential revenue streams–. –Oliceridine NDA on track for potential approval in November–. CHESTERBROOK, Pa., May ...

  • GlobeNewswire3 months ago

    Trevena to Present at the Deutsche Bank 43rd Annual Healthcare Conference

    CHESTERBROOK, Pa., May 02, 2018-- Trevena, Inc. today announced that it will be presenting at the Deutsche Bank 43 rd Annual Healthcare Conference on Tuesday, May 8 th, 2018, at 3:30 p.m. EDT in Boston, ...

  • GlobeNewswire3 months ago

    Trevena Inc. and Jiangsu Nhwa Pharmaceutical Co. Ltd Announce License Agreement for Oliceridine in China

    –Nhwa granted a license to develop, manufacture, and commercialize oliceridine in China–. –Trevena to receive upfront and milestone payments and royalties–. CHESTERBROOK, Pa. and XUZHOU, China, May 01, ...

  • GlobeNewswire3 months ago

    Trevena and Pharmbio Korea Announce License and Commercialization Agreement for Oliceridine in South Korea

    Trevena, Inc. (TRVN) and privately held Pharmbio Korea Inc. announced today that they have entered into an exclusive license agreement for the development and commercialization in South Korea of Trevena’s investigational product oliceridine. Under the agreement, Trevena will receive an upfront payment of $3 million, in addition to a commercialization milestone and tiered royalties on product sales ranging from high single digits to 20%.  Oliceridine is currently under review by the U.S. Food and Drug Administration for potential approval in the United States for the management of moderate-to-severe acute pain.

  • GlobeNewswire3 months ago

    Trevena to Report First Quarter 2018 Financial Results on May 3, 2018

    CHESTERBROOK, Pa., April 26, 2018-- Trevena, Inc. today announced that it will host a conference call and webcast on Thursday, May 3, 2018 at 8:00 am EDT to review financial results for the quarter ended ...

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • ACCESSWIRE4 months ago

    Trevena, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Trevena, Inc. (NASDAQ: TRVN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 8:00 AM Eastern Time. To listen ...